证券记录 · 已归档季度
AMLX
Amylyx Pharmaceuticals, Inc. · Healthcare · Biotechnology
18被追踪持有人
+1Δ持有人
42.12M持有股份
$572.37M报告持仓市值
+1新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +5.9% ·
股份流向 +12.7% ·
净新建仓位 +5.6%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | +11 | 60.68M | $1.09B | +14 | −2 |
| Q1 2026 | 70 | -3 | 62.54M | $868.96M | +6 | −9 |
| Q4 2025 | 73 | 0 | 62.47M | $754.72M | n/a | n/a |
| Q3 2025 | 18 | +1 | 42.12M | $572.37M | +1 | n/a |
| Q2 2025 | 14 | -1 | 33.34M | $213.68M | n/a | −1 |
| Q1 2025 | 12 | +1 | 15.66M | $55.46M | +2 | −1 |
| Q4 2024 | 11 | 0 | 5.41M | $20.47M | +1 | −1 |
| Q3 2024 | 10 | +2 | 5.23M | $16.93M | +2 | n/a |
| Q2 2024 | 8 | n/a | 10.16M | $19.31M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 11.38M | +273.3% | $154.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 7.14M | +29.6% | $97.04M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 3 | Adage Capital Partners ✦ | 6.82M | -22.5% | $92.64M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | The Vanguard Group ✦ (被动) | 5.27M | +17.2% | $71.67M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 5 | Point72 Asset Management ✦ | 2.79M | -38.5% | $37.92M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Goldman Sachs Group ✦ | 2.01M | n/a | $27.32M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Morgan Stanley ✦ | 1.95M | n/a | $26.50M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 8 | Geode Capital Management ✦ (被动) | 1.81M | +7.1% | $24.63M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | State Street Global Advisors ✦ (被动) | 1.62M | +60.7% | $22.03M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 417.77K | -72.4% | $5.68M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | Wellington Management ✦ | 236.20K | -18.2% | $3.21M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 12 | Citadel Advisors ✦ | 234.67K | -81.1% | $3.19M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 13 | T. Rowe Price ✦ | 100.44K | +9.9% | $1.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 98.42K | -82.4% | $1.34M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 73.64K | 新增 | $1.00M | 0.0% | New | 1 | SEC ↗ ×4 |
| 16 | JPMorgan Chase ✦ | 71.69K | n/a | $974,238 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 17 | D. E. Shaw & Co. ✦ | 68.88K | -54.5% | $936,038 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 19.90K | -95.0% | $270,441 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| AQR Capital Management | $1.00M | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 170 持有人, 113.99M 股份, $1.58B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 05
MILNE GEORGE M JR
Director · 30.00K 股 · $830,904
Sep 10
Cohen Joshua B
Officer, Director · 29.55K 股 · $950,040
Sep 10
Cohen Joshua B
Officer, Director · 919 股 · $30,464
Sep 10
Mazzariello Gina
Officer · 9.53K 股 · $309,140
Sep 10
Mazzariello Gina
Officer · 11 股 · $367
Sep 10
FRATES JAMES M
Officer · 9.77K 股 · $315,195
Sep 10
FRATES JAMES M
Officer · 1.04K 股 · $34,626
Sep 10
Bedrosian Camille L
Officer · 7.95K 股 · $256,004
Sep 10
Bedrosian Camille L
Officer · 2.08K 股 · $68,864
Sep 10
Klee Justin B.
Officer, Director · 29.02K 股 · $932,553
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据